Clinical Performance of Plasma Metagenomic Sequencing in Immunocompromised Pediatric Patients.

Abstract

The performance of plasma metagenomic next-generation sequencing was evaluated in an immunocompromised pediatric population. The clinical impact was limited, with management changes in 13% of cases. Moreover, organisms thought to be non-pathogenic were commonly detected. Prospective studies in specific populations are required to clarify the utility of this emerging technology.